Full TitleA Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma
The purpose of this study is to find the highest dose of cetrelimab that can be given safely with talquetamab or teclistamab in people with multiple myeloma that has come back or continued to grow despite treatment. Cetrelimab blocks a protein in the body that causes tumors to grow. Both talquetamab and teclistamab work by helping the immune system find and attack multiple myeloma cells.
Participants will receive cetrelimab with either talquetamab or teclistamab. Cetremimab is given intravenously (by vein), and talquetamab and teclistamab are given as subcutaneous (under the skin) injections.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have multiple myeloma that has come back or continued to grow despite prior treatment.
- The serious side effects of previous therapies must go away before the study treatment is given.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr Saad Usmani at 646-608-4165.